课题基金 / 基金详情

Development of Machine Learning tools for in silicon chimeric antigen receptor (CAR) design

Development of Machine Learning tools for in silicon chimeric antigen receptor (CAR) design
开发用于硅嵌合抗原受体(CAR)设计的机器学习工具
批准号:
10026469
负责人:
金额:
$50.83万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2022
资助国家:
英国
项目状态:
已结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
过继细胞疗法是一种使用患者自身改良的免疫细胞的治疗方法。它包括从病人的血液中收集T细胞——一种通常能识别和消除病原体的免疫细胞,对它们进行重新编程以识别癌细胞,并将新修饰的细胞重新引入病人体内以摧毁肿瘤。用来武装这些T细胞抵抗癌症的修饰因子被称为嵌合抗原受体,简称CAR。使用锁和钥匙的类比,正如每把锁只能用合适的钥匙打开一样,每种类型的癌症都有其独特的抗原,只能被一种特定的工程化CAR识别。目前,英国国家医疗服务体系(NHS)正在为患有复发或难以治疗的白血病和淋巴瘤的儿童和年轻人提供针对表达CD19抗原的恶性B细胞的CAR-T细胞疗法。这种疗法对化疗无效的患者尤其有效,给那些没有其他选择的患者带来了真正的希望。然而,这种CAR疗法只能治疗一种非常特定的癌症,还有很大的改进空间。针对其他癌症的特定CAR疗法的开发受到了目标发现和受体优化的繁琐过程的阻碍,coding .bio正在简化构建更好受体的过程,使其更快、更便宜、更多样化。我们的目标是帮助将这种变革性疗法带给更多的患者。
英文摘要
Adoptive cell therapy is a treatment of patients using their own, modified immune cells. It involves harvesting T cells - the immune cells that normally recognise and eliminate pathogens - from the patient's blood, reprogramming them to recognise cancer cells and re-introducing the newly modified cells back into the patient to destroy tumours. The modifying factor used to arm these T cells against cancer is called Chimeric Antigen Receptor or CAR, in short. Using the lock and key analogy, just as every lock can only be opened with the appropriate key, each type of cancer, with its unique antigens, can only be recognised by a specific engineered CAR.Currently, the National Health Service (NHS) is providing CAR-T cell therapy against malignant B cells that express antigen called CD19 to children and young adults with relapsed or difficult-to-treat leukaemia and lymphoma. The treatment is particularly effective in patients who did not respond to chemotherapy, offering real hope to those who otherwise would have no other options. However, this CAR therapy can only treat a very specific type of cancer, leaving much room for improvement. The concerted efforts into the development of specific CAR therapies against other cancers are hindered by the tedious process of target discovery and receptor optimisation.Coding.bio is streamlining the process of building better receptors, making it faster, cheaper, and more diverse. Our objective is to help bring this transformative therapy to a wider patient population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Understanding structural evolution of galaxies with machine learning
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    Nicola Rosario Napolitano
  • 依托单位: